Ryan M Rivosecchi1, Joseph Durkin1, David O Okonkwo2, Bradley J Molyneaux3. 1. Department of Pharmacy, UPMC Presbyterian Hospital, Pittsburgh, PA, USA. 2. Department of Neurologic Surgery, University of Pittsburgh, Pittsburgh, PA, USA. 3. Departments of Neurology and Critical Care Medicine, University of Pittsburgh, 3501 Fifth Avenue, BST3-7021, Pittsburgh, PA, 15213, USA. moly@pitt.edu.
Abstract
BACKGROUND: The use of vitamin K antagonists is an independent risk factor for the development of intracerebral hemorrhage (ICH). Four-factor prothrombin complex concentrate (4F-PCC) is recommended for urgent reversal of anticoagulation in this setting. The safety and efficacy of 4F-PCC in ICH with subtherapeutic levels of anticoagulation is yet to be determined. METHODS: This was a retrospective, observational study of 4F-PCC administration data from September 2013 to July 2015. Patients with spontaneous or traumatic ICH with initial INR 1.4-1.9 were compared to those with INR 2-3.9. A Fisher's exact test was used to compare the difference between the two groups in the effectiveness of 4F-PCC in reversing the INR to ≤1.3 and in the occurrence of thrombotic events within 7 days of administration. RESULTS: A total of 131 patients with a presenting INR between 1.4 and 3.9 received 4F-PCC during the study period. Twenty-three of 29 patients (79 %) in the INR <2 group achieved an INR reduction to ≤1.3 after 4F-PCC administration compared to 47 of 92 patients (51 %) in the INR 2-4 group, p = 0.03. There was no difference in thrombotic complications within 7 days after administration (6.7 % in INR 1.4-1.9 group, 10 % in INR 2-3.9 group, p = 0.73). CONCLUSION: The use of 4F-PCC in patients with INR between 1.4 and 1.9 results in an effective reduction in INR with similar thrombotic risks compared to patients presenting with an INR of 2-3.9.
BACKGROUND: The use of vitamin K antagonists is an independent risk factor for the development of intracerebral hemorrhage (ICH). Four-factor prothrombin complex concentrate (4F-PCC) is recommended for urgent reversal of anticoagulation in this setting. The safety and efficacy of 4F-PCC in ICH with subtherapeutic levels of anticoagulation is yet to be determined. METHODS: This was a retrospective, observational study of 4F-PCC administration data from September 2013 to July 2015. Patients with spontaneous or traumatic ICH with initial INR 1.4-1.9 were compared to those with INR 2-3.9. A Fisher's exact test was used to compare the difference between the two groups in the effectiveness of 4F-PCC in reversing the INR to ≤1.3 and in the occurrence of thrombotic events within 7 days of administration. RESULTS: A total of 131 patients with a presenting INR between 1.4 and 3.9 received 4F-PCC during the study period. Twenty-three of 29 patients (79 %) in the INR <2 group achieved an INR reduction to ≤1.3 after 4F-PCC administration compared to 47 of 92 patients (51 %) in the INR 2-4 group, p = 0.03. There was no difference in thrombotic complications within 7 days after administration (6.7 % in INR 1.4-1.9 group, 10 % in INR 2-3.9 group, p = 0.73). CONCLUSION: The use of 4F-PCC in patients with INR between 1.4 and 1.9 results in an effective reduction in INR with similar thrombotic risks compared to patients presenting with an INR of 2-3.9.
Entities:
Keywords:
Anticoagulants; Cerebral hemorrhage; Prothrombin complex concentrates; Vitamin K antagonist
Authors: Joshua N Goldstein; Majed A Refaai; Truman J Milling; Brandon Lewis; Robert Goldberg-Alberts; Bruce A Hug; Ravi Sarode Journal: Lancet Date: 2015-02-27 Impact factor: 79.321
Authors: Susan L Bratton; Randall M Chestnut; Jamshid Ghajar; Flora F McConnell Hammond; Odette A Harris; Roger Hartl; Geoffrey T Manley; Andrew Nemecek; David W Newell; Guy Rosenthal; Joost Schouten; Lori Shutter; Shelly D Timmons; Jamie S Ullman; Walter Videtta; Jack E Wilberger; David W Wright Journal: J Neurotrauma Date: 2007 Impact factor: 5.269
Authors: Joshua N Goldstein; Louis E Fazen; Lauren Wendell; Yuchiao Chang; Natalia S Rost; Ryan Snider; Kristin Schwab; Rishi Chanderraj; Christopher Kabrhel; Catherine Kinnecom; Emilie Fitzmaurice; Eric E Smith; Steven M Greenberg; Jonathan Rosand Journal: Neurocrit Care Date: 2008-09-23 Impact factor: 3.210
Authors: Jennifer A Frontera; John J Lewin; Alejandro A Rabinstein; Imo P Aisiku; Anne W Alexandrov; Aaron M Cook; Gregory J del Zoppo; Monisha A Kumar; Ellinor I B Peerschke; Michael F Stiefel; Jeanne S Teitelbaum; Katja E Wartenberg; Cindy L Zerfoss Journal: Neurocrit Care Date: 2016-02 Impact factor: 3.210
Authors: J Claude Hemphill; Steven M Greenberg; Craig S Anderson; Kyra Becker; Bernard R Bendok; Mary Cushman; Gordon L Fung; Joshua N Goldstein; R Loch Macdonald; Pamela H Mitchell; Phillip A Scott; Magdy H Selim; Daniel Woo Journal: Stroke Date: 2015-05-28 Impact factor: 7.914
Authors: Hagen B Huttner; Peter D Schellinger; Marius Hartmann; Martin Köhrmann; Eric Juettler; Johannes Wikner; Stephan Mueller; Uta Meyding-Lamade; Ralf Strobl; Ulrich Mansmann; Stefan Schwab; Thorsten Steiner Journal: Stroke Date: 2006-05-04 Impact factor: 7.914
Authors: Christopher B Allard; Sandro Scarpelini; Shawn G Rhind; Andrew J Baker; Pang N Shek; Homer Tien; Michael Fernando; Lorraine Tremblay; Laurie J Morrison; Ruxandra Pinto; Sandro B Rizoli Journal: J Trauma Date: 2009-11
Authors: Wesley R Zemrak; Kathryn E Smith; Stephen S Rolfe; Teresa May; Robert L Trowbridge; Timothy L Hayes; Gene A Grindlinger; David B Seder Journal: Neurocrit Care Date: 2017-12 Impact factor: 3.210
Authors: Denise H Rhoney; Mary La; Molly Merz; Aaron Cook; Kent A Owusu; Christina Roels; Joe Blunck; Justin Shewmaker; Kiranpal S Sangha; Salia Farrokh; John Lewin; Kathleen W Chester; Theresea Human; Kathleen Bledsoe; Kristy Greene; Melissa Levesque; Jody C Rocker; Gary Davis; Ron Neyens; Timothy F Lassiter; Sarah M Adriance Journal: Neurocrit Care Date: 2020-11-20 Impact factor: 3.210